150 related articles for article (PubMed ID: 11245343)
1. Prognostic evaluation of proliferative activity and DNA content in the phyllodes tumor of the breast: immunohistochemical and flow cytometric study of 118 cases.
Niezabitowski A; Lackowska B; Rys J; Kruczak A; Kowalska T; Mitus J; Reinfuss M; Markiewicz D
Breast Cancer Res Treat; 2001 Jan; 65(1):77-85. PubMed ID: 11245343
[TBL] [Abstract][Full Text] [Related]
2. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast.
Kleer CG; Giordano TJ; Braun T; Oberman HA
Mod Pathol; 2001 Mar; 14(3):185-90. PubMed ID: 11266524
[TBL] [Abstract][Full Text] [Related]
3. Immunoreactivity of p53, Ki-67, and c-erbB-2 in phyllodes tumors of the breast in correlation with clinical and morphologic features.
Shpitz B; Bomstein Y; Sternberg A; Klein E; Tiomkin V; Kaufman A; Groisman G; Bernheim J
J Surg Oncol; 2002 Feb; 79(2):86-92. PubMed ID: 11815995
[TBL] [Abstract][Full Text] [Related]
4. p53 protein expression and gene mutation in phyllodes tumors of the breast.
Gatalica Z; Finkelstein S; Lucio E; Tawfik O; Palazzo J; Hightower B; Eyzaguirre E
Pathol Res Pract; 2001; 197(3):183-7. PubMed ID: 11314782
[TBL] [Abstract][Full Text] [Related]
5. [Clinicopathologic features and prognostic factors of malignant phyllodes tumors].
Jia C; Mei F; Zheng J; You JF; Liu JY
Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):729-34. PubMed ID: 24447548
[TBL] [Abstract][Full Text] [Related]
6. Expression of p53 protein and Ki-67 antigen in phyllodes tumor of the breast.
Chan YJ; Chen BF; Chang CL; Yang TL; Fan CC
J Chin Med Assoc; 2004 Jan; 67(1):3-8. PubMed ID: 15077883
[TBL] [Abstract][Full Text] [Related]
7. DNA content and proliferative activity of cystosarcoma phyllodes of the breast. Potential prognostic significance.
el-Naggar AK; Ro JY; McLemore D; Garnsy L
Am J Clin Pathol; 1990 Apr; 93(4):480-5. PubMed ID: 2157332
[TBL] [Abstract][Full Text] [Related]
8. Phyllodes tumors of the breast: correlation of nucleolar organizer regions with histopathological malignancy grading, flow cytometric DNA analysis and clinical outcome.
Samaratunga H; Clarke B; Owen L; Bryson G; Swanson C
Pathol Int; 2001 Nov; 51(11):866-73. PubMed ID: 11844053
[TBL] [Abstract][Full Text] [Related]
9. Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast.
Yonemori K; Hasegawa T; Shimizu C; Shibata T; Matsumoto K; Kouno T; Ando M; Katsumata N; Fujiwara Y
Pathol Res Pract; 2006; 202(10):705-12. PubMed ID: 16889904
[TBL] [Abstract][Full Text] [Related]
10. Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer.
Railo M; Lundin J; Haglund C; von Smitten K; von Boguslawsky K; Nordling S
Acta Oncol; 1997; 36(4):369-74. PubMed ID: 9247096
[TBL] [Abstract][Full Text] [Related]
11. Ki67 and P53 Expression in Relation to Clinicopathological Features in Phyllodes Tumour of the Breast.
Mohd Ali NA; Nasaruddin AF; Mohamed SS; Wan Rahman WF
Asian Pac J Cancer Prev; 2020 Sep; 21(9):2653-2659. PubMed ID: 32986365
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial: multivariate analysis with Ki-67 index, mitotic count, and microvessel density.
Mandard AM; Denoux Y; Herlin P; Duigou F; van De Vijver MJ; Clahsen PC; van Den Broek L; Sahmoud TM; Henry-Amar M; van De Velde CJ
Cancer; 2000 Oct; 89(8):1748-57. PubMed ID: 11042570
[TBL] [Abstract][Full Text] [Related]
13. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
[TBL] [Abstract][Full Text] [Related]
14. Cystosarcoma phyllodes of the breast: histologic features, flow cytometric analysis, and clinical correlations.
Grimes MM
Mod Pathol; 1992 May; 5(3):232-9. PubMed ID: 1323101
[TBL] [Abstract][Full Text] [Related]
15. Malignant mixed Müllerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Sullivan S; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):18-24. PubMed ID: 9454654
[TBL] [Abstract][Full Text] [Related]
16. Phyllodes tumor of the breast: EGFR family expression and relation to clinicopathological features.
Suo Z; Nesland JM
Ultrastruct Pathol; 2000; 24(6):371-81. PubMed ID: 11206334
[TBL] [Abstract][Full Text] [Related]
17. Transformation in recurrent ovarian granulosa cell tumors: Ki67 (MIB-1) and p53 immunohistochemistry demonstrates a possible molecular basis for the poor histopathologic prediction of clinical behavior.
Costa MJ; Walls J; Ames P; Roth LM
Hum Pathol; 1996 Mar; 27(3):274-81. PubMed ID: 8600043
[TBL] [Abstract][Full Text] [Related]
18. Expression of anaphase-promoting complex7 in fibroadenomas and phyllodes tumors of breast.
Kang Y; Kim JH; Lee TH; Kim TS; Jung WH; Chung HC; Park BW; Sheen SS; Han JH
Hum Pathol; 2009 Jan; 40(1):98-107. PubMed ID: 18789487
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Molecular and Biological Characteristics of Phyllodes Tumors of the Breast.
Vorotnikov IK; Vysotskaya IV; Denchik DA; Letyagin VP; Davydov MM; Kirsanov VY; Kim EA; Buseva VS
Bull Exp Biol Med; 2020 Oct; 169(6):806-810. PubMed ID: 33098518
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder.
Gontero P; Casetta G; Zitella A; Ballario R; Pacchioni D; Magnani C; Muir GH; Tizzani A
Eur Urol; 2000 Sep; 38(3):287-96. PubMed ID: 10940702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
